Çѱ¹À¯¹æ¾ÏÇÐȸ 2023 Ãß°èÇмú´ëȸ : 2023-10-14
±³À°ÀÏÀÚ : 2023-10-14
±³À°Àå¼Ò : ±×·£µåÁ¶¼±Á¦ÁÖ º»°ü2Ãþ ±×·£µåº¼·ë, ÇѶóȦ
±³À°ÁÖÁ¦ : 2023 Ãß°èÇмú´ëȸ
ÁÖÃÖ±â°ü : Çѱ¹À¯¹æ¾ÏÇÐȸ
´ã´çÀÚ : Á¤Áö¿µ
¿¬¶ôó : 02-3461-6060
À̸ÞÀÏ : kbcs@kbcs.or.kr
±³À°Á¾·ù : ¿Ü°ú
Âü¼®¿¹»óÀÎ : 350¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª : Á¦ÁÖƯº°ÀÚÄ¡µµ
±³À°½Ã°£ : 9 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 200,000¿ø
ºñ°í "Á¤È¸¿ø, ÁØȸ¿ø 150,000¿ø Àü°øÀÇ, °£È£»ç 100,000¿ø ºñȸ¿ø 200,000¿ø"
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10¿ù 14ÀÏ ±×·£µåº¼·ë 09:10~09:35 Personalized endocrine treatments and CDK4/6 inhibitors for high risk ER positive breast cancer ¾È¼º±Í(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ±×·£µåº¼·ë 09:35~10:00 Best therapeutic strategy for HER2 positive breast cancer with high risk of relapse ¼°æÁø(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ±×·£µåº¼·ë 10:00~10:25 Integrating immunotherapy and PARP inhibitors into the standard-of-care for triple negative breast cancer ÀÌÁöÀº(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ±×·£µåº¼·ë 10:25~10:50 Beginning the journey of HER2-low disease Á¶ÀºÀ±(¼º±Õ°üÀÇ´ë)
ÈÞ½Ä 10¿ù 14ÀÏ 10:50~11:10 BREAK ( )
±³À°½Ã°£ 10¿ù 14ÀÏ ±×·£µåº¼·ë 11:10~11:35 Recent trends of breast cancer surgery in Korea_real world practice of breast and axillary management ÃÖÁ¤Àº(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ±×·£µåº¼·ë 11:35~12:00 Do all microcalcifications need to be removed with mastectomy for excellent responders? ¹è¼ö¿¬(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ±×·£µåº¼·ë 12:00~12:25 Recent updates and ongoing trials of de-escalating local treatment ÀÌÇѺ°(¼¿ïÀÇ´ë)
½Ä»ç 10¿ù 14ÀÏ ±×·£µåº¼·ë 12:25~14:00 LUNCH ( )
±³À°½Ã°£ 10¿ù 14ÀÏ ±×·£µåº¼·ë 14:00~14:25 Newly defined 'pregnancy associated breast cancer' Á¤ÀçÈ£(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ±×·£µåº¼·ë 14:25~14:50 Understanding lobular breast cancer_perhaps more than a gentle ductal carcinoma ±èÁöÇü(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ±×·£µåº¼·ë 14:50~15:15 How to better monitor disease recurrence after standard treatment: Is radiology enough? would ctDNA monitoring lead to survival benefit? ±èÁö¼±(¿ï»êÀÇ´ë)
ÈÞ½Ä 10¿ù 14ÀÏ 15:15~15:35 BREAK ( )
±³À°½Ã°£ 10¿ù 14ÀÏ ±×·£µåº¼·ë 15:35~16:00 Fertility preservation for young age patients with breast cancer ÀÌ´Ù¿ë(º¸¶ó¸Åº´¿ø)
±³À°½Ã°£ 10¿ù 14ÀÏ ±×·£µåº¼·ë 16:00~16:25 Optimal timing for prophylactic surgeries ÀÌÁö¿¬(°æºÏÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ±×·£µåº¼·ë 16:25~16:50 Endocrine therapies for women with low bone mineral density Á¤¹Î¼º(ÇѾçÀÇ´ë)
±âŸ 10¿ù 14ÀÏ ÇѶóȦ 09:10~09:20 ÀÓ»ó½ÃÇèÀ§¿øȸ ¼Ò°³ ¹× ÇöȲ À¯Á¾ÇÑ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ÇѶóȦ 09:20~09:30 Necessity of post-mastectomy radiotherapy in breast cancer patients with excellent response after neoadjuvant chemotherapy : A phase 3, multicenter, randomized controlled study (NEMESIS, KBCSG-26) ¹è¼þÁØ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ÇѶóȦ 09:30~09:40 Male breast cancer (OASIS project) Â÷ġȯ(ÇѾçÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ÇѶóȦ 09:40~09:50 Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS) ¾È¼º±Í(¿¬¼¼ÀÇ´ë)
±âŸ 10¿ù 14ÀÏ ÇѶóȦ 09:50~10:00 µî·Ï»ç¾÷À§¿øȸ ¼Ò°³ ¹× ÇöȲ Á¤¼Ò¿¬(±¹¸³¾Ï¼¾ÅÍ)
±âŸ 10¿ù 14ÀÏ ÇѶóȦ 10:00~10:15 K-CURE °ø°øµ¥ÀÌÅÍ ¼Ò°³ äÈñÁ¤(±¹¸³¾Ï¼¾ÅÍ)
±âŸ 10¿ù 14ÀÏ ÇѶóȦ 10:15~11:30 µî·Ï»ç¾÷À§¿øȸ ¿ì¼ö ¿¬±¸ ¼Ò°³ ±è¿ë¼®(°¡Å縯ÀÇ´ë)
±âŸ 10¿ù 14ÀÏ ÇѶóȦ 10:30~10:50 Panel discussion ¹è¼þÁØ(¿¬¼¼ÀÇ´ë) Â÷ġȯ(ÇѾçÀÇ´ë) ¾È¼º±Í(¿¬¼¼ÀÇ´ë) äÈñÁ¤(±¹¸³¾Ï¼¾ÅÍ) ±è¿ë¼®(°¡Å縯ÀÇ´ë)( )
ÈÞ½Ä 10¿ù 14ÀÏ 10:50~11:10 BREAK ( )
±³À°½Ã°£ 10¿ù 14ÀÏ ÇѶóȦ 11:10~11:25 Çѱ¹ÀÇ À¯¹æ¾Ï ÀÎ½Ä Çâ»ó Ä·ÆäÀÎÀÇ °ú°Å¿Í ÇöÀç ³ëµ¿¿µ(Â÷ÀÇ°úÇдë)
±³À°½Ã°£ 10¿ù 14ÀÏ ÇѶóȦ 11:25~11:40 ÇÎÅ©¸®º» Ä·ÆäÀÎÀº Áö¼ÓµÇ¾î¾ß Çϴ°¡ ±è±æ¿ø(¿¬ÇÕ´º½º)
±³À°½Ã°£ 10¿ù 14ÀÏ ÇѶóȦ 11:40~11:55 Çѱ¹ À¯¹æ¾Ï ÀÎ½Ä Çâ»ó Ä·ÆäÀÎÀÇ ¹Ì·¡ ½ÅÇõÀç(ÇѾçÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ÇѶóȦ 11:55~12:10 Advocacy beyond awareness: driving policy change and research funding À̹ÎÇõ(¼øõÇâÀÇ´ë)
Åä·Ð 10¿ù 14ÀÏ ÇѶóȦ 12:10~12:25 Panel discussion À̹ÎÇõ(¼øõÇâÀÇ´ë) ½ÅÇõÀç(ÇѾçÀÇ´ë) ±è±æ¿ø(¿¬ÇÕ´º½º) ¹ÎÅ¿ø(±¹¹ÎÀϺ¸) ÀÌÁøÇÑ(µ¿¾ÆÀϺ¸)( )
½Ä»ç 10¿ù 14ÀÏ 12:25~14:00 LUNCH ( )
±³À°½Ã°£ 10¿ù 14ÀÏ ÇѶóȦ 14:00~14:15 À¯¹æ¾Ï ÀûÁ¤¼ºÆò°¡ ¹× ÇâÈÄ°úÁ¦ ±è³²·É(°Ç°º¸Çè½É»çÆò°¡¿ø)
±³À°½Ã°£ 10¿ù 14ÀÏ ÇѶóȦ 14:15~14:30 À¯¹æ¾Ï ³»¿ë ¼Ò°³¿Í ÇöȲ °û¹ü¼®(µ¿±¹ÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ÇѶóȦ 14:30~14:40 ÇöÀå¿¡¼ÀÇ °æÇè°ú À̽´ (1) ¹Ú¼¼È£(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ÇѶóȦ 14:40~14:50 ÇöÀå¿¡¼ÀÇ °æÇè°ú À̽´ (2) ±è±¸»ó(°í½ÅÀÇ´ë)
Åä·Ð 10¿ù 14ÀÏ ÇѶóȦ 14:50~15:15 Panel discussion °û¹ü¼®(µ¿±¹ÀÇ´ë) ¹Ú¼¼È£(¿¬¼¼ÀÇ´ë) ±è±¸»ó(°í½ÅÀÇ´ë) À±ÇöÁ¶(ÀüºÏÀÇ´ë)( )
±³À°½Ã°£ 10¿ù 14ÀÏ ÇѶóȦ 15:35~16:00 Interactive communication in the era of digital healthcare ÀÌÁ¾¿ø(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ÇѶóȦ 16:00~16:25 ÃÊÀ½ÆÄÀ̹ÌÁö ±â¹Ý ÀΰøÀ¯¹æº¸Çü¹° Áø´Ü ÀΰøÁö´É ÇÁ·Î±×·¥ °³¹ß ±èÀçÈ«(´õ´õºíÀ¯ÀÇ¿ø)
±³À°½Ã°£ 10¿ù 14ÀÏ ÇѶóȦ 16:25~16:50 ChatGPT: ¿¬±¸ ¹× Áø·á¿¡ÀÇ È°¿ë¹æ¾È ±ÇÇö¿í(¿ï»êÀÇ´ë)